Ferrosa Therapeutics AG

Based in Switzerland, Ferrosa Therapeutics AG is focused on developing innovative biologics to treat anemia of inflammation, primarily affecting patients with chronic kidney disease, cancer, and autoimmune disorders. Founded in 2026, Ferrosa Therapeutics AG is based in Basel, Switzerland, and specializes in biologics aimed at treating anemia of inflammation. The company conducted its most recent funding round in April 2026, raising USD 3. 5 million in Seed funding led by Forty51 Ventures, marking its first investment target.

The founder's history and further details about potential subsidiaries are not disclosed. Ferrosa Therapeutics specializes in developing next-generation biologics aimed at treating anemia of inflammation, a condition prevalent among patients with chronic kidney disease (CKD), cancer, and autoimmune disorders. The company’s lead product, a bispecific antibody, is engineered to target two clinically validated drivers of anemia of inflammation simultaneously, addressing the inadequacies of existing treatments such as erythropoietin stimulating agents (ESAs) and intravenous (IV) iron. These current treatments often provide incomplete benefits and are less effective for patients whose anemia is driven primarily by inflammation rather than iron deficiency.

Ferrosa's innovative therapy is designed for self-administration, offering a long-acting formulation that allows for subcutaneous dosing every three months. The company aims to serve a global market, focusing particularly on regions with high incidences of CKD, cancer, and autoimmune disorders, such as North America and Europe. Ferrosa Therapeutics operates within a structured transaction framework primarily focused on partnerships and collaborations in the biopharmaceutical sector. The company engages with healthcare providers, hospitals, and specialty clinics that treat patients suffering from anemia of inflammation, facilitating the distribution of its lead bispecific antibody product.

Revenue generation is driven by agreements with these healthcare entities that may involve direct sales or partnership models for clinical use in addressing anemia in targeted patient populations. Flagship products are positioned to cater to the significant unmet medical need in the addressable market, which exceeds USD 35 bn, with potential for widespread chronic use across various indications. Transactions are structured to ensure accessibility and affordability of the company's offerings to the healthcare system and patients. In April 2026, Ferrosa Therapeutics AG raised USD 3.

5 million in Seed funding led by Forty51 Ventures. The company will use the funding to advance its bispecific antibody program to treat anemia of inflammation in conditions like chronic kidney disease, autoimmune disorders, and cancer. Plans for future growth include the design and launch of new products targeted at addressing anemia of inflammation, with expansion plans set for key markets such as North America and Europe.